ClinicalTrials.gg
Status unknownNCT05633095Updated Mar 24, 2023

The Pilot Study of Medical Device-Neuclare for Patients With Mild Cognitive Disorder and Early Dementia

An interventional study of Neuclare in Dementia, Mild and Cognitive Disorder Mild, sponsored by Deepsonbio. Status unknown at 2 sites in Korea, Republic of. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by Deepsonbio · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Dementia with a site in Korea, Republic of — 15 open to participants now, 18 under way, 4 of them phase 3. Dementia · Korea, Republic of.

Planned enrollment
42nd of 43
20 · median 220
Started
2022
with 3 others
No phase
13 of 52
5 open now
Registered
32nd of 52
by date

Among the 52 studies in Dementia with a site in Korea, Republic of, this one is the 42nd largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2022, is one of 13 with no phase, and was the 32nd registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

15 of the 52 studies in Dementia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Dementia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical trial aims to explore the effectiveness and safety of cognitive function improvement of Neuclare, a science medical device, for patients with mild cognitive impairment and early Alzheimer's disease.

Through methods such as Trail Making Test Black \& White, Attention Questionnaire Scale(AQS), Neuropsychiatric Inventory (NPI), etc, cognitive function improvement before and after using Neuclare will be evaluated.

03

Conditions studied

  • Dementia, Mild
  • Cognitive Disorder Mild
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 55 to 90
  • Patients who meet "Probable Alzheimer's disease" and ", 4th edition (DSM-IV)" criteria for dementia
  • Patients with CDR (clinical dementia rating) from 0.5 to 1 and -II over 18
  • Upon hearing and fully understanding the detailed explanation of this clinical trial, a person who has voluntarily decided to participate and agreed in writing to comply with the precautions

Exclusion criteria

Exclusion Criteria:

  • Patient with pathological lesions in the brain identified by MRI
  • Patients with metabolic disorders such as thyroid dysfunction, hyperglycemia, hypoglycemia, liver or kidney dysfunction, and long-term use of drugs that will cause cognitive decline (e.g., anticholinergic drugs)
  • History of epileptic seizures or depression or psychiatric abnormalities or with visual acuity and fluctuations in cognitive decline
  • History of psychiatric disorder other than the inclusion criteria.
  • A person with a severe history of cancer/tuberculosis
  • A person who has or is taking psychiatric or peripheral/central nervous system drugs
  • A person who has contact dermatitis or sensitive skin abnormalities
  • Patients with a high fever of 40 degrees or higher based on eardrum body temperature
  • A person whose bleeding is identified within the last 3 months due to a common procedure/surgery that may affect vital signs
  • A person who is unable to perform MRI tests
  • Pregnant women
  • Patient with calcification in the brain identified by CT
  • Patient with allergic to contrast agents such as Definity or Gadovist
  • Other cases where the investigator judged that it is difficult to participate in the study;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment group

    The patient with mild cognitive disorder and early dementia who will be treated with the medical device-Neuclare

    Device: Neuclare

Interventions

  • DeviceNeuclare

    It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.

06

What researchers measure

Primary outcomes

  1. Change of Trail Making Test Black & White Score : From Baseline to Week 5

    Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Trail Making Test Black \& White Score

    Time frame: Week 5

Secondary outcomes

  1. Change of Attention Questionnaire Scale : From Baseline to Week 5

    Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Attention Questionnaire Scale

    Time frame: Week 5

  2. Change of Neuropsychiatric Inventory Score : From Baseline to Week 5

    Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Neuropsychiatric Inventory score

    Time frame: Week 5

  3. Change of Quality of life-AD Score : From Baseline to Week 5

    Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Quality of life-AD Score

    Time frame: Week 5

  4. Change of MMSE-II Score : From Baseline to Week 5

    Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by MMSE-II Score

    Time frame: Week 5

  5. change of beta-amyloid deposition measured by Amyloid PET-CT : From Baseline to Week 5

    change of beta-amyloid deposition with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as measured by Amyloid PET-CT

    Time frame: Week 5

  6. Change of glucose metabolic rate in brain measured by FDG PET-CT : From Baseline to Week 5

    Compare glucose metabolic rate with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as measured by FDG PET-CT

    Time frame: Week 5

  7. Change of Aβ oligomer density measured by MDS-OAβ test result : From Baseline to Week 5

    Compare Aβ oligomer density with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as measured by MDS-OAβ test

    Time frame: Week 5

07

Study locations

2 of 2 sites recruiting
  • Hallym University Dongtan Sacred Heart Hospital
    Hwaseong-si, Gyeonggi-do 18450, Korea, Republic of
    Recruiting
    • Seonkyu Kim · Contactksksbs@deepsonbio.com · +82 10-4324-5147
    • Jaeho Kim, M.D. Ph.D · Principal investigator
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
    Recruiting
    • Seonkyu Kim · Contactksksbs@deepsonbio.com · +82-10-4324-5147
    • SangYun Kim, M.D. Ph.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jul 2023, 9 months after the start.

Of 46 industry-sponsored interventional studies with no phase under Dementia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 9 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 1, 2022
StartActual
Oct 7, 2022
Primary completionEst.
Jul 31, 2023
CompletionEst.
Mar 30, 2024
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05633095
Lead sponsor
Deepsonbio
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Oct 7, 2022
Primary completion
Jul 31, 2023 (estimated)
Completion
Mar 30, 2024 (estimated)
Last update
Mar 24, 2023

Study contacts

Seonkyu Kim
Contact
ksksbs@deepsonbio.com
+82-10-4324-5147
SangYun Kim, M.D. ph.D
principal investigator · Seoul National University Bundang Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion